Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449327 | 0.98 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL1449332 | 0.98 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL4899462 | 0.98 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL10420077 | 0.96 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL11683525 | 0.94 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL10420504 | 0.94 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL8993117 | 0.94 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL140525 | 0.94 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL10420078 | 0.90 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL10419027 | 0.90 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024078581-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND USES THEREOF | APPICINE THERAPEUTICS (HK) LIMITED (CN) | 2024-04-18 | — | — | WO | disclosed |
| US-20240101584-A1 | TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES | Westlake University (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4284790-A1 | TARGETED DELIVERY OF 1, 2, 4, 5-TETRAOXANE COMPOUNDS AND THEIR USES | Westlake University (CN) | 2023-12-06 | — | — | EP | disclosed |
| CN-117157281-A | Targeted delivery of 1,2,4, 5-tetraoxacompounds and uses thereof | 西湖大学 | 2023-12-01 | — | — | CN | disclosed |
| WO-2021150170-A1 | AMINE COMPOUND, REACTIVE COALESCING AGENT, COATING COMPOSITION, COATING LAYER AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-07-29 | — | — | WO | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101584-A1 | TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES | AIFM2, GPX1, GPX4 | HDAC3 1448/4885HDAC1 605/4885HDAC2 543/4885 |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | HDAC3 642/4885HDAC1 1060/4885HDAC2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.